Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) Comparison with companies in other sectors?

Harrow Health, Inc. 11.875% Senior Notes due 2027 has a share price of 51.58M. You can analyze Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) competitors across different market sectors through stock heatmaps.

What are HROWM's NET and operating margins?

Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) operating margin is around 0.05, and net profit margin is approximately -0.09 as of the latest reports.

In what way does HROWM's earnings per share (EPS) trend reflect its financial momentum?

Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) EPS is N/A (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Harrow Health, Inc. 11.875% Senior Notes due 2027 is N/A, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Harrow Health, Inc. 11.875% Senior Notes due 2027?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Harrow Health, Inc. 11.875% Senior Notes due 2027 like P/E which is -53.57, P/B which is 13.44, and PEG which is -1.12. Compare them with sector averages to evaluate if the stock is priced fairly.

Harrow Health, Inc. 11.875% Senior Notes due 2027

HROWM•NASDAQ

Healthcare

Medical - Pharmaceuticals

$26.28

$-0.01(-0.06%)

Fundamental Analysis of Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

P/E Ratio

ROE

-0.28%

Net Margin

-0.09%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$1.36B

Shares OutstandingTotal number of shares issued

$51.58M

Book Value/ShareNet worth per share

$1.94

Revenue/ShareAnnual revenue per share

$5.57

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

Net MarginNet income as percentage of revenue

-8.76%

Operating MarginOperating income as percentage of revenue

4.55%

ROEReturn on shareholders' equity

-28.40%

ROAReturn on total assets

-4.49%

ROCEReturn on capital employed

3.05%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.67

Cash/ShareCash and equivalents per share

$1.32

FCF YieldFree cash flow as percentage of market cap

-1.75%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$2.97

Dividend YieldAnnual dividend as percentage of stock price

11.28%

Financial Ratios Analysis data is not available for HROWMFinancial Ratios Analysis details for HROWM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for HROWMSector Benchmarking details for HROWM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Harrow Health, Inc. 11.875% Senior Notes due 2027 Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Harrow Health, Inc. 11.875% Senior Notes due 2027. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Harrow Health, Inc. 11.875% Senior Notes due 2027's unique business strengths and challenges.

Key Financial Metrics for Harrow Health, Inc. 11.875% Senior Notes due 2027

For Harrow Health, Inc. 11.875% Senior Notes due 2027, essential financial indicators include EPS -, PE -, and ROE -0.28. These key ratios reveal insights into Harrow Health, Inc. 11.875% Senior Notes due 2027's profitability, valuation, and operational health. Understanding these metrics enables you to compare Harrow Health, Inc. 11.875% Senior Notes due 2027 with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Harrow Health, Inc. 11.875% Senior Notes due 2027

Metrics like Net Margin -8.76% and ROA -4.49% shed light on how well Harrow Health, Inc. 11.875% Senior Notes due 2027 is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Harrow Health, Inc. 11.875% Senior Notes due 2027 can sustain its operations and continue growing in the future.

Valuation and Market Position of Harrow Health, Inc. 11.875% Senior Notes due 2027

Using ratios such as P/B Ratio 13.44 and PEG Ratio -1.12, investors can assess whether Harrow Health, Inc. 11.875% Senior Notes due 2027 is appropriately valued based on its financials and growth potential. These figures, combined with Harrow Health, Inc. 11.875% Senior Notes due 2027's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Harrow Health, Inc. 11.875% Senior Notes due 2027

Financial health indicators, such as Debt/Equity Ratio 3.29 and Cash Flow $-0.67, provide a snapshot of Harrow Health, Inc. 11.875% Senior Notes due 2027's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Harrow Health, Inc. 11.875% Senior Notes due 2027, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Harrow Health, Inc. 11.875% Senior Notes due 2027

Investing in Harrow Health, Inc. 11.875% Senior Notes due 2027 based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Harrow Health, Inc. 11.875% Senior Notes due 2027 focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;